Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
MARI.VI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.22
N/A
-1.23
vs -1.42
Q2.22
N/A
-1.37
vs -1.55
Q3.22
N/A
-1.29
vs -1.30
Q4.22
N/A
-0.40
vs 0.28
Q1.23
N/A
-1.37
vs -1.23
Q2.23
N/A
-0.96
vs -1.37
Q3.23
N/A
-1.38
vs -1.29
Q4.23
N/A
-0.78
vs -0.40
Q1.24
N/A
-1.39
vs -1.37
Q2.24
N/A
-5.65
vs -0.96
Sales Growth
YoY
Current
Estimates
Q3.22
-12%
2.2M vs 2.5M
Q4.22
-29%
4.2M vs 5.9M
Q1.23
+38%
3.3M vs 2.4M
Q2.23
-23%
1.9M vs 2.5M
Q3.23
-12%
1.9M vs 2.2M
Q4.23
-52%
2M vs 4.2M
Q1.24
-78%
737.5K vs 3.3M
Q2.24
-10%
1.7M vs 1.9M
Q1.25
+280%
2.8M vs 737.5K
Q2.25
+62%
2.8M vs 1.7M
Return on Equity
QoQ
Q3.22
+55%
0.55
vs 1.04
Q4.22
+15%
0.15
vs 0.55
Q1.23
+37%
0.37
vs 0.15
Q2.23
+21%
0.21
vs 0.37
Q3.23
+23%
0.23
vs 0.21
Q4.23
+12%
0.12
vs 0.23
Q1.24
+18%
0.18
vs 0.12
Q2.24
+42%
0.42
vs 0.18
Institutionnal Ownership
Forecast
103%2025-Revenue
322%2025-EPS
-49%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics
Relative Strength
MARI.VI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
VIE
Unprofitable
Unprofitable
-0.50Â ( -2.56%)
Relative Strenght
Volume Buzz
-22%
Earning Acce
No
Dist 52w H.
4%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How MARI.VI compares to sector?
MARI.VI
-2x